Do analysts rate AVIR or MLTX?

MoonLake Immunotherapeutics has a consensus price target of $24.21, indicating a potential upside of 27.11%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.41

Which has higher earnings and valuation, AVIR or MLTX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is AVIR or MLTX more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media favor AVIR or MLTX?

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 8 mentions for MoonLake Immunotherapeutics and 5 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.42 beat MoonLake Immunotherapeutics' score of 0.39 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AVIR or NNNN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, AVIR or NNNN?

Anbio Biotechnology has higher revenue and earnings than Atea Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Anbio Biotechnology $8.65M 158.36 $6.40M N/A N/A

Is AVIR or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Anbio Biotechnology N/A N/A N/A

Do analysts recommend XERS or AVIR?

Xeris Biopharma currently has a consensus target price of $10.80, suggesting a potential upside of 25.58%. Given Xeris Biopharma's higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to XERS or AVIR?

In the previous week, Atea Pharmaceuticals had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 3 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.54 beat Atea Pharmaceuticals' score of 0.42 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AKTS or AVIR?

Aktis Oncology currently has a consensus target price of $34.60, suggesting a potential upside of 44.41%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aktis Oncology 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is AKTS or AVIR more profitable?

Aktis Oncology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Atea Pharmaceuticals N/A -57.01% -51.49%

Does the media refer more to AKTS or AVIR?

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 4 mentions for Aktis Oncology. Atea Pharmaceuticals' average media sentiment score of 0.42 beat Aktis Oncology's score of 0.39 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AVIR or INBX?

Inhibrx Biosciences has a consensus price target of $150.00, indicating a potential upside of 78.38%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Inhibrx Biosciences 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is AVIR or INBX more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Inhibrx Biosciences N/A -563.90% -72.32%

Does the media prefer AVIR or INBX?

In the previous week, Atea Pharmaceuticals had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 2 mentions for Inhibrx Biosciences. Atea Pharmaceuticals' average media sentiment score of 0.42 beat Inhibrx Biosciences' score of 0.34 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Atea Pharmaceuticals (AVIR) Competitors

$4.78 -0.09 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$4.75 -0.03 (-0.63%)

As of 07:34 PM Eastern

Compare

AVIR vs. MLTX, NNNN, XERS, AKTS, and INBX

Should you buy Atea Pharmaceuticals stock or one of its competitors? MarketBeat compares Atea Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atea Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), Anbio Biotechnology (NNNN), Xeris Biopharma (XERS), Aktis Oncology (AKTS), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Atea Pharmaceuticals (NASDAQ:AVIR) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Atea Pharmaceuticals' return on equity of -57.01% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

MoonLake Immunotherapeutics has a consensus price target of $24.21, indicating a potential upside of 27.11%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 8 mentions for MoonLake Immunotherapeutics and 5 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.42 beat MoonLake Immunotherapeutics' score of 0.39 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Atea Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Summary

Atea Pharmaceuticals beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Anbio Biotechnology?

Atea Pharmaceuticals (NASDAQ:AVIR) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has higher revenue and earnings than Atea Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Anbio Biotechnology	$8.65M	158.36	$6.40M	N/A	N/A

In the previous week, Atea Pharmaceuticals had 5 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 0 mentions for Anbio Biotechnology. Atea Pharmaceuticals' average media sentiment score of 0.42 beat Anbio Biotechnology's score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Anbio Biotechnology	Neutral

Atea Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, meaning that its stock price is 415% more volatile than the broader market.

Summary

Atea Pharmaceuticals beats Anbio Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Xeris Biopharma currently has a consensus target price of $10.80, suggesting a potential upside of 25.58%. Given Xeris Biopharma's higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Xeris Biopharma has a net margin of 3.81% compared to Atea Pharmaceuticals' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Xeris Biopharma has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	5.09	$550K	$0.06	143.33
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

In the previous week, Atea Pharmaceuticals had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 3 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.54 beat Atea Pharmaceuticals' score of 0.42 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Summary

Xeris Biopharma beats Atea Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 4 mentions for Aktis Oncology. Atea Pharmaceuticals' average media sentiment score of 0.42 beat Aktis Oncology's score of 0.39 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aktis Oncology has higher revenue and earnings than Atea Pharmaceuticals. Aktis Oncology is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	196.84	-$63.73M	-$0.38	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Aktis Oncology currently has a consensus target price of $34.60, suggesting a potential upside of 44.41%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Aktis Oncology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Summary

Aktis Oncology beats Atea Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Inhibrx Biosciences?

Atea Pharmaceuticals (NASDAQ:AVIR) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Atea Pharmaceuticals' return on equity of -57.01% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Inhibrx Biosciences has a consensus price target of $150.00, indicating a potential upside of 78.38%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Atea Pharmaceuticals had 3 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 5 mentions for Atea Pharmaceuticals and 2 mentions for Inhibrx Biosciences. Atea Pharmaceuticals' average media sentiment score of 0.42 beat Inhibrx Biosciences' score of 0.34 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Atea Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, indicating that its stock price is 241% more volatile than the broader market.

Inhibrx Biosciences has higher revenue and earnings than Atea Pharmaceuticals. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Inhibrx Biosciences	$1.30M	948.92	-$140.05M	-$8.39	N/A

Summary

Atea Pharmaceuticals beats Inhibrx Biosciences on 9 of the 14 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$389.73M	$3.69B	$6.90B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-2.27	20.49	27.10	23.94
Price / Sales	N/A	300.39	517.51	91.92
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.35	7.92	10.66	6.14
Net Income	-$158.35M	$23.81M	$3.60B	$331.74M
7 Day Performance	0.84%	-1.27%	-1.51%	-1.72%
1 Month Performance	9.63%	2.56%	1.11%	-1.44%
1 Year Performance	42.26%	42.49%	23.77%	16.97%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	0.9403 of 5 stars	$4.78 -1.8%	N/A	+44.9%	$389.73M	N/A	N/A	70	Analyst Forecast
MLTX MoonLake Immunotherapeutics	2.9868 of 5 stars	$19.52 -4.4%	$24.21 +24.0%	-62.9%	$1.50B	N/A	N/A	2	Analyst Forecast
NNNN Anbio Biotechnology	0.2903 of 5 stars	$9.51 -4.6%	N/A	N/A	$1.43B	$8.65M	N/A	27	Gap Down
XERS Xeris Biopharma	3.2568 of 5 stars	$8.28 +1.5%	$10.80 +30.4%	+72.2%	$1.41B	$291.85M	138.00	290
AKTS Aktis Oncology	2.215 of 5 stars	$25.17 -1.6%	$34.60 +37.5%	N/A	$1.37B	$6.50M	N/A	76	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MLTX, NNNN, XERS, AKTS, and INBX

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Summary

How does Atea Pharmaceuticals compare to Anbio Biotechnology?

Summary

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Summary

How does Atea Pharmaceuticals compare to Aktis Oncology?

Summary

How does Atea Pharmaceuticals compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MLTX, NNNN, XERS, AKTS, and INBX

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Is AVIR or MLTX more profitable?

Do analysts rate AVIR or MLTX?

Does the media favor AVIR or MLTX?

Which has higher earnings and valuation, AVIR or MLTX?

Do institutionals and insiders hold more shares of AVIR or MLTX?

Which has more volatility and risk, AVIR or MLTX?

Summary

How does Atea Pharmaceuticals compare to Anbio Biotechnology?

Do institutionals & insiders hold more shares of AVIR or NNNN?

Do analysts recommend AVIR or NNNN?

Is AVIR or NNNN more profitable?

Which has higher valuation & earnings, AVIR or NNNN?

Does the media prefer AVIR or NNNN?

Which has more volatility and risk, AVIR or NNNN?

Summary

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Do institutionals & insiders have more ownership in XERS or AVIR?

Do analysts recommend XERS or AVIR?

Is XERS or AVIR more profitable?

Which has better earnings & valuation, XERS or AVIR?

Does the media refer more to XERS or AVIR?

Which has more volatility and risk, XERS or AVIR?

Summary

How does Atea Pharmaceuticals compare to Aktis Oncology?

Does the media refer more to AKTS or AVIR?

Do institutionals & insiders have more ownership in AKTS or AVIR?

Which has better earnings & valuation, AKTS or AVIR?

Do analysts recommend AKTS or AVIR?

Is AKTS or AVIR more profitable?

Summary

How does Atea Pharmaceuticals compare to Inhibrx Biosciences?

Is AVIR or INBX more profitable?

Do analysts rate AVIR or INBX?

Does the media prefer AVIR or INBX?

Do institutionals & insiders believe in AVIR or INBX?

Which has more risk & volatility, AVIR or INBX?

Which has stronger valuation and earnings, AVIR or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools